Evidence map›Paper›PMID 34372775›Full record

ArticleBMC gastroenterology2021

Prevalence of sero-markers and non-invasive assessment of liver cirrhosis in patients with Hepatitis B virus infection in Freetown, Sierra Leone: a cross-sectional study.

Sulaiman Lakoh, Emmanuel Firima, Darlinda F Jiba, Matilda N Kamara, Wadzani Gashau, Gibrilla F Deen, Olukemi Adekanmbi, George A Yendewa

Open access · goldAbstract read
In one paragraph

Article in BMC gastroenterology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 6 papers.

0numbers the graph read from it
0cells of the map it votes in
6citing papers in PubMed
1.4field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

6 citing papers in PubMed, 10 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 4 countries.

Sulaiman LakohDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Switzerland. lakoh2009@gmail.com.
Emmanuel FirimaClinical Research Unit, Department of Medicine, Swiss Tropical and Public Health Institute, Basel, Switzerland.
Darlinda F JibaDepartment of Medicine, University of Sierra Leone Teaching Hospitals Complex, Freetown, Switzerland.
Matilda N KamaraDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Switzerland.
Wadzani GashauDepartment of Medicine, University of Maiduguri Teaching Hospital, Maiduguri, Nigeria.
Gibrilla F DeenDivision of Infectious Diseases, Department of Internal Medicine, College of Medicine and Allied Health Sciences, University of Sierra Leone, Freetown, Switzerland.
Olukemi AdekanmbiDepartment of Medicine, University of Ibadan, Ibadan, Nigeria.
George A YendewaDepartment of Medicine, Case Western Reserve University School of Medicine, Cleveland, OH, USA.
University of Sierra Leone · SLUniversity College Hospital, Ibadan · NGUniversity of Basel · CHUniversity of Maiduguri · NGUniversity School · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundHepatitis B virus (HBV) is a major global health problem. Although sub-Saharan Africa has a high proportion of the global burden of HBV, the epidemiology and clinical features of HBV in this region are poorly characterized, and access to diagnostic and treatment services remain limited.

methodsWe conducted a retrospective study of HBV-infected children and adults of all age groups who were evaluated at public and private health facilities in Freetown, Sierra Leone between January 2017 and January 2019. We assessed their clinical presentation, HBV sero-markers, stages of liver disease, prevalence of cirrhosis by non-invasive tools, and the proportion of treatment eligible patients using the criteria recommended by the World Health Organization's 2015 treatment guidelines for HBV. Logistic regression was used to identify predictors of liver cirrhosis.

results163 HBV patients included in the study, with mean age 32.6 years and 65.0% (106) being males. Most (84.0%) were asymptomatic at presentation. The majority (69.9%) were classified as having HBeAg-negative chronic infection (or inactive HBsAg carrier phase), 24.5% were in the HBeAg-negative immune active phase, 3.1% had HBeAg positive hepatitis, and 2.5% were HBsAg negative. The median Aspartate aminotransferase to Platelet Ratio (APRI) and Fibrosis-4 (FIB-4) scores were 0.37 and 0.80, respectively. The prevalence of cirrhosis was 7.6% and 6.2%, estimated by the APRI and FIB-4 scores, respectively. About 20.0% of patients were eligible for treatment with antiviral agents. Based on APRI scores, the presence of any symptom [adjusted odds ratio (aOR) 20.0, 95% confidence interval (CI) (4.1-85.9); p < 0.001], elevated direct bilirubin [aOR 12.1, 95% CI (1.9-63.0); p = 0.003], and elevated total bilirubin [aOR 16.1, 95% CI (3.2-80.8); p = 0.001] were independent predictors of cirrhosis.

conclusionAlthough most patients with HBV infection were asymptomatic, the prevalence of liver cirrhosis and proportion of patients requiring antiviral treatment were substantial. This small study from a hyperendemic setting in Sierra Leone suggests that routine population-based screening may increase early detection and linkage of HBV patients to care before development of complications. Larger studies are needed to confirm our findings.

Indexed as

Hepatitis BHepatitis B, ChronicAdultChildCross-Sectional StudiesHepatitis B Surface AntigensHepatitis B virusHumansLiver CirrhosisMalePrevalenceRetrospective StudiesSierra LeoneHepatitis B Surface AntigensCirrhosisHBVLiver fibrosisResource-limited settingsSierra Leone

Identifiers

PMID34372775
PMCPMC8353767
OpenAlexW3192508765

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.